216 related articles for article (PubMed ID: 19650675)
1. Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.
Hénin E; Tod M; Trillet-Lenoir V; Rioufol C; Tranchand B; Girard P
Clin Pharmacokinet; 2009; 48(6):359-69. PubMed ID: 19650675
[TBL] [Abstract][Full Text] [Related]
2. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
Mu S; Ludden TM
J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
[TBL] [Abstract][Full Text] [Related]
3. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Extrapolation Methods to Predict Trough Concentrations to Guide Therapeutic Drug Monitoring of Oral Anticancer Drugs.
Janssen JM; Dorlo TPC; Beijnen JH; Huitema ADR
Ther Drug Monit; 2020 Aug; 42(4):532-539. PubMed ID: 32384536
[TBL] [Abstract][Full Text] [Related]
5. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
[TBL] [Abstract][Full Text] [Related]
6. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369
[TBL] [Abstract][Full Text] [Related]
7. Adaptive control methods for the dose individualisation of anticancer agents.
Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
[TBL] [Abstract][Full Text] [Related]
8. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
[TBL] [Abstract][Full Text] [Related]
9. Do we need full compliance data for population pharmacokinetic analysis?
Girard P; Sheiner LB; Kastrissios H; Blaschke TF
J Pharmacokinet Biopharm; 1996 Jun; 24(3):265-82. PubMed ID: 8970015
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
Bonate PL; Floret S; Bentzen C
Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
[TBL] [Abstract][Full Text] [Related]
11. Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life.
Choi S; Jeon S; Yim DS; Han S
Drug Des Devel Ther; 2020; 14():811-821. PubMed ID: 32158198
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
Klein CE; Kastrissios H; Miller AA; Hollis D; Yu D; Rosner GL; Grinblatt DL; Larson RA; Ratain MJ
Cancer Chemother Pharmacol; 2006 Jan; 57(2):199-206. PubMed ID: 16158312
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
[TBL] [Abstract][Full Text] [Related]
16. Simulation for clinical repeated-dose pharmacokinetic trials applying a peak-and-trough sampling design to estimate oral clearance.
Ishida K; Kayano Y; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2007 Nov; 30(11):2159-62. PubMed ID: 17978492
[TBL] [Abstract][Full Text] [Related]
17. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
Lehr T; Staab A; Trommeshauser D; Schaefer HG; Kloft C
Clin Pharmacokinet; 2010; 49(1):53-66. PubMed ID: 20000889
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients.
Le Guellec C; Bourgoin H; Büchler M; Le Meur Y; Lebranchu Y; Marquet P; Paintaud G
Clin Pharmacokinet; 2004; 43(4):253-66. PubMed ID: 15005639
[TBL] [Abstract][Full Text] [Related]
19. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
20. Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data.
Abrantes JA; Jönsson S; Karlsson MO; Nielsen EI
Br J Clin Pharmacol; 2019 Jun; 85(6):1326-1336. PubMed ID: 30767254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
